ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Capsaicin: Drug information

Capsaicin: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Capsaicin: Patient drug information" and "Capsaicin: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Alivio [OTC];
  • Allevess [OTC];
  • Arthritis Pain Relieving [OTC];
  • Asperflex Hot Pain Relieving [OTC];
  • Axsain [OTC] [DSC];
  • Bio-Therm Pain Relieving [OTC] [DSC];
  • Capsaicin HP [OTC];
  • Capsaicin Topical Pain Patch [OTC];
  • Capsiderm [OTC];
  • Capzix [OTC];
  • Castiva Warming [OTC];
  • Circata [OTC];
  • Dendracin Neurodendraxcin [OTC];
  • DermacinRx Circatrix [OTC];
  • DermacinRx Penetral [OTC];
  • Douleurin [OTC] [DSC];
  • Levatio;
  • Limencin [OTC];
  • MenCaps [OTC];
  • Menthozen Hydrogel [OTC];
  • New Terocin [OTC];
  • Qutenza;
  • Qutenza (2 Patch);
  • Qutenza (4 Patch);
  • Reliever [OTC];
  • Renovo [DSC];
  • Salonpas Pain Rel Gel-Ptch Hot [OTC];
  • Salonpas-Hot [OTC];
  • Sure Result SR Relief [OTC];
  • Zostrix HP [OTC];
  • Zostrix Natural Pain Relief [OTC];
  • Zostrix-HP [OTC] [DSC]
Pharmacologic Category
  • Analgesic, Topical;
  • Topical Skin Product;
  • Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist
Dosing: Adult
Muscle/joint pain

Muscle/joint pain: Topical:

Cream, gel, liquid, lotion: Apply thin film to affected areas 3 to 4 times daily.

Patch: 0.025%, 0.03%, 0.0375%: Apply 1 patch to affected area for up to 8 hours (maximum: 4 patches/day); do not use for >5 consecutive days (product specific).

Neuropathic pain

Neuropathic pain: Topical: Patch (Qutenza): Apply patch to most painful area for 60 minutes. Up to 4 patches may be applied in a single application. Treatment may be repeated ≥3 months as needed for return of pain (do not apply more frequently than every 3 months).

Neuropathic pain associated with diabetes mellitus

Neuropathic pain associated with diabetes mellitus:

Note: May require ~8 to 12 weeks of treatment at a therapeutic dose to adequately assess efficacy (Ref).

Cream (0.075%) (off-label use): Topical: Apply 4 times/day to painful areas associated with neuropathy (Ref).

Patch (Qutenza): Topical: Apply patch to most painful areas of the feet for 30 minutes. Up to 4 patches may be applied in a single application. Treatment may be repeated ≥3 months as needed for return of pain (do not apply more frequently than every 3 months).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Capsaicin: Pediatric drug information")

Muscle ache and joint pain, minor

Muscle ache and joint pain, minor: Topical:

Lotion 0.025% (DiabetAid Tingling and Pain Relief): Children ≥8 years and Adolescents: Topical: Apply to affected area not more than 3 to 4 times/day.

Patch: Note: With OTC products, approved ages and uses may vary; consult product-specific labeling.

Product strength <0.05%:

Children ≥12 years and Adolescents: Topical:

Levatio (0.03%): Apply 1 patch to affected area for up to 8 hours; change patch 1 to 2 times daily; maximum daily dose: 4 patches/day; do not use for >5 consecutive days.

MenCaps (0.0225%): Apply 1 patch to affected area for up to 8 hours; may change patch up to 3 times daily.

Releevia MC (0.0375%), Renovo (0.0375%): Apply 1 patch to affected area; may change patch 1 to 2 times daily; maximum daily dose: 3 patches/day.

Salonpas Pain Relieving Hot Patch (0.025%): Apply 1 patch to affected area for up to 8 hours; may change patch up to 3 to 4 times daily.

Product strength 0.05%: Adolescents ≥16 years: Topical: Allevess patch: Apply 1 patch to affected area; may change patch 1 to 2 times daily.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. The following adverse events occurred with topical patch administration.

>10%:

Local: Application-site burning (14%), application-site erythema (2% to 63%), application-site pain (10% to 42%)

Neuromuscular & skeletal: Limb pain (11%)

1% to 10%:

Cardiovascular: Hypertension (2%)

Dermatologic: Excoriation of skin (2%), papule of skin (application site: 6%), pruritus (2%)

Gastrointestinal: Nausea (5%), vomiting (3%)

Local: Application-site edema (2% to 4%), application-site pruritus (6%), local dryness of skin (application site: 2%)

Nervous system: Headache (3%)

Respiratory: Bronchitis (2%), cough (2%), nasopharyngitis (4%), sinusitis (3%), upper respiratory tract infection (4%)

<1%:

Cardiovascular: Palpitations, tachycardia

Dermatologic: Skin blister

Local: Application-site reaction (includes dermatitis, hyperesthesia, paresthesia, urticaria)

Nervous system: Dizziness, dysesthesia

Ophthalmic: Eye pruritus

Postmarketing:

Dermatologic: Burn (second and third degree), cicatrix of skin,

Nervous system: Abnormal sensory symptoms

Contraindications

Hypersensitivity to capsaicin, menthol, or any component of the formulation.

OTC labeling: When used for self-medication, do not use on wounds, damaged, broken, irritated skin, or into skin folds; do not cover with bandage; do not apply within 1 hour before or after bath, shower, hot tub, or sauna; do not use in combination with external heat source (eg, heating pad); do not use concurrently with other topical analgesics.

Warnings/Precautions

Concerns related to adverse effects:

• Burns: May cause serious burns (eg, first- to third-degree chemical burns) at the application site. In some cases, hospitalization has been required. Discontinue use and seek medical attention if signs of skin injury (eg, pain, swelling, or blistering) occur following application (FDA Drug Safety Communication 2012).

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).

• Irritation (8% patch): Severe irritation to the eyes, mucous membranes, respiratory tract, or skin may occur due to unintended capsaicin exposure. If irritation of the eyes or mucous membranes occurs, remove the individual from the area of the capsaicin patch and flush eyes and mucous membranes with cool water. If respiratory tract irritation (eg, coughing, sneezing) occurs, remove the individual from the area of the capsaicin patch and provide supportive care if shortness of breath develops; if respiratory irritation worsens or does not resolve, do not re-expose affected individual to capsaicin. Ensure procedures (eg, avoiding unnecessary contact with items in room, including horizontal surfaces and bedsheets, administering in well-ventilated area) and protective measures (eg, face mask, nitrile gloves, protective glasses) are used during administration. If skin not intended to be treated is exposed to the patch, apply cleansing gel for 1 minute and remove with dry gauze; after cleansing gel has been removed, wash the area with soap and water; postapplication pain should be treated with local cooling methods (ice pack) and/or analgesics. Clean all areas that had contact with capsaicin

• Sensory function reduction (8% patch): Decreased sensory function, including to thermal and other harmful stimuli, has been reported; effects are usually minor and temporary. Patients with preexisting sensory deficits should be assessed for sensory deterioration or loss prior to each patch application. Continued use should be reevaluated for new onset or worsening of existing sensory deficits.

Disease-related concerns:

• Cardiovascular disease: Use the 8% patch with caution in patients with uncontrolled hypertension or a history of cardiovascular events; transient increases in BP due to treatment-related pain have occurred during and after application. Monitor BP periodically during and following treatment.

• Cerebrovascular disease: Use the 8% patch with caution in patients with a history of cerebrovascular events; transient increases in BP due to treatment-related pain have occurred during and after application of RX patch. Monitor BP periodically during and following treatment.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

• Patch (8%): Avoid inhaling airborne material from dried residue. Remove patches gently and slowly to decrease risk of aerosolization; inhalation of airborne capsaicin may result in coughing or sneezing.

Other warnings/precautions:

• Appropriate use: For external use only; avoid contact with eyes, mouth, genitals, or any or other mucous membranes. Do not use immediately before or after activities such as bathing, swimming, showering, sunbathing, strenuous exercise, steam bath, sauna, or other heat or sunlight exposure to the treated area. Stop use and consult a health care provider if excessive redness, blistering burning or irritation develops, symptoms get worse, symptoms persist for >7 days, symptoms resolve and then recur, or if difficulty breathing or swallowing occurs. Do not handle contact lenses for 1 hour after handling, applying, or removing capsaicin (product specific).

• OTC labeling: Transient burning may occur and generally disappears after several days.

• RX labeling: Do not cover with bandage or compression. Use only on intact skin; do not use on wounds, damaged, broken, infected, sensitive, or inflamed skin. Do not apply to face or scalp. Do not use concurrently with other external pain-relieving products.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Cream, External:

Arthritis Pain Relieving: 0.075% (57 g) [odor free; contains benzyl alcohol, cetyl alcohol]

Axsain: 0.25% (60 g [DSC]) [contains benzyl alcohol, cetyl alcohol]

Capsaicin HP: 0.1% (60 g) [contains cetearyl alcohol, propylene glycol, trolamine (triethanolamine)]

Capsaicin HP: 0.1% (56.6 g) [odor free; contains benzyl alcohol, cetyl alcohol]

Capzix: 0.1% (56.6 g) [contains benzyl alcohol, cetyl alcohol]

Circata: 0.05% (57 g) [contains cetearyl alcohol]

DermacinRx Circatrix: 0.05% (57 g) [contains cetearyl alcohol]

DermacinRx Penetral: 0.025% (118 mL, 237 mL) [contains capsicum oleoresin, trolamine (triethanolamine)]

Sure Result SR Relief: 0.025% (118 mL) [contains cetearyl alcohol, trolamine (triethanolamine)]

Zostrix HP: 0.1% (56.6 g [DSC]) [odor free; contains benzyl alcohol, cetyl alcohol]

Zostrix HP: 0.1% (56.6 g) [odorless; contains benzyl alcohol, cetyl alcohol]

Zostrix Natural Pain Relief: 0.033% (56.6 g) [odor free; contains benzyl alcohol, cetyl alcohol]

Generic: 0.025% (25 g, 50 g, 60 g, 120 g); 0.075% (120 g); 0.1% (42.5 g, 60 g)

Kit, External:

Qutenza: 8% [packaged with cleansing gel] [contains edetate (edta) disodium, polyethylene glycol (macrogol)]

Qutenza (2 Patch): 8% [packaged with cleansing gel] [contains edetate (edta) disodium, polyethylene glycol (macrogol)]

Qutenza (4 Patch): 8% [packaged with cleansing gel] [contains edetate (edta) disodium, polyethylene glycol (macrogol)]

Lotion, External:

Bio-Therm Pain Relieving: 0.002 % (113.4 g [DSC]) [contains cetearyl alcohol, trolamine (triethanolamine)]

Castiva Warming: 0.035% (113 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben, sd alcohol 40b]

Dendracin Neurodendraxcin: Capsaicin 0.025% and menthol 10% and methyl salicylate 30% (60 mL, 120 mL) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben, soybean lecithin, trolamine (triethanolamine)]

Douleurin: 0.025% (120 mL [DSC]) [contains cetyl alcohol, propylene glycol, trolamine (triethanolamine)]

Limencin: 0.025% (120 mL) [contains cetyl alcohol, iodopropynyl butylcarbamate, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]

New Terocin: 0.025% (10 mL, 120 mL) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]

Patch, External:

Alivio: 0.03% [contains menthol 5%] (15 ea) [contains polysorbate 80]

Allevess: 0.05% [contains menthol 5%] (15 ea)

Asperflex Hot Pain Relieving: 0.025% [contains menthol 1.25%] (6 ea) [contains edetate (edta) disodium, propylene glycol]

Capsaicin Topical Pain Patch: 0.025% (5 ea) [contains edetate (edta) disodium, polysorbate 80, propylene glycol]

Capsiderm: 0.0375% [contains menthol 5%] (15 ea) [contains polysorbate 80]

Levatio: 0.03% [contains menthol 5%] (15 ea) [contains polysorbate 80]

MenCaps: 0.0225 % (15 ea) [contains disodium edta, methylparaben, polysorbate 80, propylparaben]

Menthozen Hydrogel: 0.03% [contains menthol 4%] (5 ea) [contains edetate (edta) disodium, methylparaben, polysorbate 80]

Reliever: 0.05% [contains menthol 5%] (15 ea)

Renovo: 0.0375% [contains menthol 5%] (3 ea [DSC], 15 ea [DSC]) [contains edetate (edta) disodium, methylparaben, polysorbate 80, propylparaben]

Salonpas Pain Rel Gel-Ptch Hot: 0.025% [contains menthol 1.25%] (6 ea) [contains edetate (edta) disodium, propylene glycol]

Salonpas-Hot: 0.025% (3 ea)

Generic: 0.025% (5 ea, 10 ea); 0.0225 % (15 ea [DSC])

Stick, External:

Zostrix-HP: 0.075% (1 g [DSC]) [contains propylene glycol, triclosan]

Generic Equivalent Available: US

May be product dependent

Pricing: US

Cream (Capsaicin External)

0.025% (per gram): $6.84 - $7.00

0.075% (per gram): $5.30

0.1% (per gram): $0.33

Cream (Circata External)

0.05% (per gram): $33.77

Cream (DermacinRx Circatrix External)

0.05% (per gram): $33.77

Cream (DermacinRx Penetral External)

0.025% (per mL): $11.44

Cream (Zostrix HP External)

0.1% (per gram): $0.23

Cream (Zostrix Natural Pain Relief External)

0.033% (per gram): $0.34

Kit (Qutenza (2 Patch) External)

8% (per each): $2,122.56

Kit (Qutenza (4 Patch) External)

8% (per each): $4,245.12

Kit (Qutenza External)

8% (per each): $1,061.28

Lotion (Castiva Warming External)

0.035% (per gram): $0.11

Lotion (Dendracin Neurodendraxcin External)

0.025-10-30% (per mL): $3.87

Patch (Alivio External)

0.03-5% (per each): $59.83

Patch (Asperflex Hot Pain Relieving External)

0.025-1.25% (per each): $0.79

Patch (Capsaicin External)

0.025% (per each): $52.20 - $52.60

Patch (Menthozen Hydrogel External)

0.03-4% (per each): $48.00

Patch (Salonpas Pain Rel Gel-Ptch Hot External)

0.025-1.25% (per each): $1.73

Patch (Salonpas-Hot External)

0.025% (per each): $1.84

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Topical products (cream, gel, liquid, lotion): Avoid contact with eyes and mucous membranes. Gently rub into painful area until thoroughly absorbed. Wash hands with soap and water immediately after applying (unless hands are part of the treatment area). If applying cream to hands, wait 30 minutes before washing hands.

Topical patch:

≤0.05% products: Apply patch externally to clean and dry affected area. Remove protective film prior to application. May cut patch to desired size prior to removing the film (product specific). Do not use within 1 hour prior to a bath or immediately after bathing. Do not use with a heating pad.

8% product (Qutenza): Patch should only be applied by a health care provider in a well-ventilated area. The treatment area must be identified and marked by the health care provider. May cut patch (prior to removing the protective release liner) to match size/shape of treatment area. If necessary, excessive hair present on and surrounding the treatment area may be clipped (not shaved). Prior to application, the treatment area should be cleansed with mild soap and water and dried thoroughly. If needed, the treatment area and surrounding 1 to 2 cm may be anesthetized with a topical anesthetic prior to patch application to reduce application discomfort; keep the local anesthetic in place until the skin is anesthetized and then remove with a dry wipe; cleanse area again with soap/water and dry thoroughly. Keep patch in sealed pouch until immediately before use; patch may then be applied to dry, intact skin using nitrile gloves (latex gloves should not be used). Use of a face mask and protective glasses are also recommended during application. During administration, avoid unnecessary contact with items in room (eg, items patient may later have contact with, including bedsheets, horizontal surfaces). If applying to feet, examine feet to detect skin lesions prior to patch application. During application, slowly peel back the release liner under the patch and use other hand to smooth patch onto skin. If applying to feet, patch may be wrapped around the dorsal, lateral, and plantar surfaces of each foot to completely cover treatment area. Patch should remain in place for 30 minutes if applying to feet or 60 minutes for all other areas; to ensure patch remains on treatment area, a dressing (eg, rolled gauze) may be used. Remove patches gently and slowly by rolling adhesive side inward. Following patch removal, apply cleansing gel to the treatment area and leave in place for at least 1 minute. Remove cleansing gel with a dry wipe and gently wash the area with mild soap and water and dry thoroughly. Clean all areas that came in contact with patch; all treatment materials (including used and unused cut patches, associated packaging, cleansing gel, gloves, other treatment materials) should be disposed of according to biomedical waste procedures.

Administration: Pediatric

Topical:

Cream, gel, liquid, and lotion: Avoid contact with eyes and mucous membranes. Avoid applying on wounds, damaged, or irritated skin. Gently rub into painful area until thoroughly absorbed. Wash hands with soap and water immediately after applying (unless hands are part of the treatment area). If applying cream to hands, wait 30 minutes before washing hands. Do not use with a heating pad. Avoid direct exposure of treated area to heat or sunlight. Do not bandage.

Patch: Product strength ≤0.05%: Avoid contact with face, scalp, eyes, mouth, and mucous membranes. Avoid applying on wounds or damaged or sensitive skin. Apply patch externally to clean and dry affected area. Remove protective film prior to application. May cut patch to desired size prior to removing the film (product specific). Do not use within 1 hour prior to a bath or immediately after bathing. Do not use with a heating pad or any compression bandage or device. Wash hands with soap and water after applying.

Use: Labeled Indications

Muscle/Joint pain: Temporary relief of minor aches and pains of muscles and joints associated with simple backache, muscle strains, sprains, arthritis, bruises, or cramps.

Neuropathic pain (8% patch): Management of neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy of the feet in adults.

Use: Off-Label: Adult

Burning mouth syndrome (topical); Neuropathic pain associated with diabetes mellitus; Pain associated with psoriasis and intractable pruritus

Medication Safety Issues
Sound-alike/look-alike issues:

Zostrix may be confused with Zestril, Zovirax

Metabolism/Transport Effects

Substrate of CYP2E1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Systemic absorption is limited following topical administration of the patch, and fetal exposure is not expected following maternal use; plasma concentrations are below the limit of detection 3 to 6 hours after the patch is removed.

Breastfeeding Considerations

Systemic absorption is limited following topical administration of the 8% patch, and exposure via breast milk is not expected following maternal use.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. To minimize potential exposure to a breastfed infant, avoid application to the nipple and surrounding area.

Monitoring Parameters

8% patch: BP periodically during and following treatment; sensory deficits.

Mechanism of Action

Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations followed by pain relief mediated by a reduction in TRPV1-expressing nociceptive nerve endings, a process that has been described as nociceptor defunctionalization (Anand 2011).

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: OTC products (capsaicin 0.025% to 0.1%): 2 to 4 weeks of continuous therapy; Qutenza patch: 1 week after application

Absorption: Topical patch (capsaicin 8%): Systemic absorption is transient and low (<5 ng/mL) in approximately one-third of patients when measured following 60-minute application. In patients with quantifiable concentrations, most fell below the limit of quantitation at 3 to 6 hours post application.

Half-life elimination: Topical patch (capsaicin 8%): 1.64 hours (Babbar 2009)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Qutenza;
  • (AT) Austria: Abc | Abc lokale schmerz therapie waerme | Qutenza;
  • (AU) Australia: Zo rub oa | Zostrix;
  • (BD) Bangladesh: Capsi | Ostocin | Topicacin;
  • (BE) Belgium: Qutenza;
  • (BG) Bulgaria: Capsamol dolor | Qutenza;
  • (BR) Brazil: Moment;
  • (CH) Switzerland: Isola capsicum n | Qutenza;
  • (CL) Chile: Cesamid | Presyc;
  • (CO) Colombia: Capsaicina | Caritas parche leon cadera | Casacine | Hansaplast parche termico leon | Qutenza;
  • (CZ) Czech Republic: Qutenza;
  • (DE) Germany: Abc | Abc waerme creme | Advel Thermobalsam | Capsicum | Hansaplast abc waerme | Hansaplast med lokale schmerz-ter.abc waerme | Qutenza;
  • (DK) Denmark: Qutenza;
  • (DO) Dominican Republic: Parche termico leon;
  • (EC) Ecuador: Hansaplast Leontos | Qutenza;
  • (EE) Estonia: Capsitop | Reumaplast;
  • (EG) Egypt: Capsin | Magicapsaicin;
  • (ES) Spain: Capsicin | Capsicum farmaya | Hansaterm | Picasum | Qutenza | Sensedol;
  • (FI) Finland: Qutenza;
  • (FR) France: Qutenza;
  • (GB) United Kingdom: Qutenza;
  • (GR) Greece: Arthralgon | Capsaxin | CAPSER | Gelcen | Leontos | Qutenza | Zacin;
  • (HU) Hungary: Qutenza;
  • (ID) Indonesia: Capzacin;
  • (IE) Ireland: Axsain | Qutenza | Zacin;
  • (IL) Israel: Zostrix | Zostrix hp;
  • (IN) India: Capsain;
  • (IR) Iran, Islamic Republic of: Capsicin medipharm;
  • (IT) Italy: Qutenza;
  • (KR) Korea, Republic of: Diaxen | Dipental | Zostrix;
  • (LT) Lithuania: Qutenza;
  • (LV) Latvia: Qutenza;
  • (MT) Malta: Qutenza;
  • (MX) Mexico: Capsidol ps;
  • (MY) Malaysia: Astrapharm chilli brand | Menzza Np | Menzza Oa;
  • (NL) Netherlands: Qutenza;
  • (NO) Norway: Capsina | Qutenza;
  • (NZ) New Zealand: ABC Heat Plaster | Zostrix;
  • (PL) Poland: Capsagamma | Qutenza;
  • (PR) Puerto Rico: Arthritis Formula Cream Capsaicin | Capzasin hp | Capzasin p | Qutenza | Theragen | Theragen hp | Zostrix | Zostrix hp foot pain relief cream | Zostrix sports | Zostrix stick;
  • (PT) Portugal: Hansaplast Emplastro Termico | Neodor | Qutenza;
  • (QA) Qatar: Salonpas-Hot;
  • (RO) Romania: Qutenza;
  • (RU) Russian Federation: Qutenza;
  • (SE) Sweden: Capsina | Qutenza;
  • (SG) Singapore: Menzza Oa | Theragen;
  • (SI) Slovenia: Qutenza;
  • (SK) Slovakia: Capsagamma | Qutenza;
  • (TH) Thailand: Capsika 75;
  • (TR) Turkey: Capciderm;
  • (TW) Taiwan: Capderm;
  • (UG) Uganda: Topicacin;
  • (ZA) South Africa: Osteoeze rub
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490-502. doi:10.1093/bja/aer260 [PubMed 21852280]
  3. Babbar S, Marier JF, Moukassi MS, et al. Pharmacokinetic Analysis of Capsaicin After Topical Administration of High-Concentration Capsaicin Patch to Patients With Peripheral Neuropathic Pain. Ther Drug Monit. 2009;31(4):502-510. [PubMed 19494795]
  4. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, A High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia: A Randomised, Double-Blind Study. Lancet Neurol. 2008;7(12):1106-1112. [PubMed 18977178]
  5. Bernstein JE, Korman NJ, Bickers DR, et al. Topical Capsaicin Treatment of Chronic Postherpetic Neuralgia. J Am Acad Dermatol. 1989;21(2, pt 1):265-270. [PubMed 2768576]
  6. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol. 1986;15(3):504-507. doi:10.1016/s0190-9622(86)70201-6 [PubMed 3760276]
  7. Buchanan J, Zakrzewska J. Burning Mouth Syndrome. Clin Evid (online). March 14, 2008. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf [PubMed 19450321]
  8. Capzasin HP Arthritis Pain Relief Cream (capsaicin) [prescribing information]. Chattanooga, TN: Chattem Inc; received February 2020.
  9. Capzasin Liquid (capsaicin) [prescribing information]. Chattanooga, TN: Chattem Inc; January 2010.
  10. Capzasin Quick Relief Gel (capsaicin 0.025%) [prescribing information]. Chattanooga, TN: Chattem Inc; January 2010.
  11. Capzix (capsaicin 0.1%) [prescribing information]. Glencoe, IL: TopRail Medical Products; July 2019.
  12. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  13. DermacinRx (capsaicin) [prescribing information]. San Fernando, CA: PureTek Corporation; received July 2020.
  14. Diabet Aid (capsaicin) [prescribing information]. Tarrytown, NY: Insight Pharmaceuticals; October 2019.
  15. Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol. 1993;29(3):438-442. doi:10.1016/0190-9622(93)70208-b [PubMed 7688774]
  16. Flexin (capsaicin and menthol) [prescribing information]. Tampa, FL: Whyteman Labs LLC; November 2015.
  17. Food and Drug Administration (FDA) Drug Safety Communication. Rare Cases of Serious Burns With the Use of Over-the-Counter Topical Muscle and Joint Pain Relievers. 2012. http://www.fda.gov/Drugs/DrugSafety/ucm318858.htm
  18. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  19. Levatio Patch (capsaicin 0.03%) [prescribing information]. Hollywood, FL: Alivio Medical Products; March 2015.
  20. MenCaps Patch (capsaicin) [prescribing information]. Los Angeles, CA: Alexso Inc; August 2015.
  21. Mínguez Serra MP, Salort Llorca C, Silvestre Donat FJ. Pharmacological treatment of burning mouth syndrome: A review and update. Med Oral Patol Oral Cir Bucal. 2007;12(4):E299-304. [PubMed 17664916]
  22. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R. Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study. J Oral Pathol Med. 2004;33(2):111-114. [PubMed 14720197]
  23. Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee. Neurology. 2022;98(1):31-43. doi:10.1212/WNL.0000000000013038 [PubMed 34965987]
  24. Qutenza (capsaicin 8%) [prescribing information]. Morristown, NJ: Averitas Pharma Inc; March 2023.
  25. Qutenza (capsaicin 8%) [prescribing information]. Morristown, NJ: Averitas Pharma Inc; February 2023.
  26. Renovo (capsaicin and menthol) [prescribing information]. Marietta, GA: TMIG Inc; January 2015.
  27. Salonspas Hot (capsaicin) [prescribing information]. Florham Park, NJ: Hisamitsu America Inc; received May 2020.
  28. Silvestre FJ, Silvestre-Rangil J, Tamarit-Santafé C, Bautista D. Application of a capsaicin rinse in the treatment of burning mouth syndrome. Med Oral Patol Oral Cir Bucal. 2012;17(1):e1-4. doi:10.4317/medoral.17219 [PubMed 21743415]
  29. Spice R, Hagen NA. Capsaicin in burning mouth syndrome: titration strategies. J Otolaryngol. 2004;33(1):53-54. doi:10.2310/7070.2004.00053 [PubMed 15291279]
  30. SR Relief (capsaicin 0.025%) [prescribing information]. Wilmington, DE: Intl. Brand Management; received June 2017.
  31. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group. Arch Intern Med. 1991;151(11):2225-2229. doi:10.1001/archinte.151.11.2225 [PubMed 1953227]
  32. Willcockson HH, Chen Y, Han JE, et al. Effect of Genetic Deletion of the Vanilloid Receptor TRPV1 on the Expression of Substance P in Sensory Neurons of Mice With Adjuvant-Induced Arthritis. Neuropeptides. 2010;44(4):293-297. [PubMed 20303589]
  33. Zostrix HP Arthritis Pain Relief (capsaicin) [prescribing information]. Lake Forest, IL: Akorn Inc; June 2015.
  34. Zostrix HP Foot Pain Relief Cream (capsaicin) [prescribing information]. Ann Arbor, MI: Akorn Consumer Health; 2015.
Topic 8840 Version 322.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟